CN Patent

CN101945851A — 肽基腈和其作为二肽基肽酶i抑制剂的用途

Assigned to AstraZeneca AB · Expires 2011-01-12 · 15y expired

What this patent protects

本发明提供了式(I)的化合物、其制备方法、含有其的药物组合物和其作为二肽基肽酶I(DPPI)抑制剂的用途，其中n、y、X 1 、X 2 、A、B、R 1 、R 2 、R 3 、R 4 和R 5 如说明书中所定义。

USPTO Abstract

本发明提供了式(I)的化合物、其制备方法、含有其的药物组合物和其作为二肽基肽酶I(DPPI)抑制剂的用途，其中n、y、X 1 、X 2 、A、B、R 1 、R 2 、R 3 、R 4 和R 5 如说明书中所定义。

Drugs covered by this patent

Patent Metadata

Patent number
CN101945851A
Jurisdiction
CN
Classification
—
Expires
2011-01-12
Drug substance claim
No
Drug product claim
No
Assignee
AstraZeneca AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.